Rani Therapeutics has raised $234 million across multiple rounds, including Series C tranches in 2015 ($15.5M & $7.65M), Series D tranches (2017–2018: $39M and undisclosed) and Series E activity in 2020 (two tranches: $50M and $69M), plus a $60.3M Post-IPO round on Oct 23, 2025. Founded in 2012, Rani develops an innovative oral-delivery platform (RaniPill) for biologics, targeting conditions traditionally treated by injection. Funding supported device engineering, GLP/GMP manufacturing scale-up, preclinical and clinical programs, and strategic collaborations with pharma partners to broaden therapeutic applications.